Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Revance Therapeutics Inc shares valued at $9,096 were sold by Jordan Erica on Apr 16 ’24. At $3.80 per share, Jordan Erica sold 2,392 shares. The insider’s holdings dropped to 114,864 shares worth approximately $0.76 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Sjuts Dustin S sold 9,211 shares, netting a total of over 46,446 in proceeds. Following the sale of shares at $5.04 each, the insider now holds 167,550 shares.
Before that, Moxie Dwight had sold 8,125 shares from its account. In a trade valued at $40,971, the CLO & GC traded Revance Therapeutics Inc shares for $5.04 each. Upon closing the transaction, the insider’s holdings decreased to 8,125 shares, worth approximately $0.91 million.
As published in a research note from Mizuho on January 29, 2024, Revance Therapeutics Inc [RVNC] has been rated down from a Buy to a Neutral and the price target has been revised to $9 from $16. Analysts at Goldman downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early January. As of August 16, 2023, Exane BNP Paribas has increased its “an Underperform” rating to a “Neutral” for RVNC. Earlier on October 11, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for RVNC stock.
Analyzing RVNC Stock Performance
Over the course of the year, Revance Therapeutics Inc shares have dropped approximately -25.03%. Shares of the company reached a 52-week high of $9.74 on 01/02/24 and a 52-week low of $2.30 on 06/26/24. A 50-day SMA is recorded $3.80, while a 200-day SMA reached $5.11. Nevertheless, trading volume fell to 5.66 million shares from 13.34 million shares the previous day.
Support And Resistance Levels for Revance Therapeutics Inc (RVNC)
According to the 24-hour chart, there is a support level at 6.58, which, if violated, would cause prices to drop to 6.57. In the upper region, resistance lies at 6.60. The next price resistance is at 6.61. RSI (Relative Strength Index) is 77.16 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.25, which suggests the price will increase in the coming days. Percent R is at 1.54%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
